Here are the DEF 14A proxy statements from Amgen Inc (AMGN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow AMGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMGN filings page.
Amgen Inc. is asking stockholders to vote at its May 19, 2026 virtual annual meeting on four items: electing 12 directors, an advisory “Say on Pay” vote, ratifying Ernst & Young as auditor for 2026, and a stockholder proposal for an independent board chair, which the Board recommends voting against.
The proxy highlights strong 2025 execution, including 10% year-over-year revenue and sales growth, record sales for 18 products, 14 products each exceeding $1 billion in sales, and five U.S. FDA approvals. Amgen reports 37% sales growth in its biosimilar portfolio to $3 billion and notes that more than 25% of revenue comes from non-U.S. markets.
The company is investing heavily in U.S. manufacturing, following a prior $1 billion North Carolina expansion with additional commitments of $900 million in Ohio and $650 million in Puerto Rico, aimed at boosting capacity, yields, and supply resilience. Executive pay is described as performance-based, with 80% of annual long-term equity awards tied to performance and a 2025 annual incentive plan payout at 136% of target based on financial and strategic results.